Literature DB >> 1159704

Potential central nervous system antitumor agents. Hydantoin derivatives.

G W Peng, V E Marquez, J S Driscoll.   

Abstract

Hydantoin derivatives of varying lipophilic character were prepared as nitrogen mustard carriers for CNS antitumor evaluation. Activity was studied in the murine ependymoblastoma brain tumor system. Multiple cures were observed for three of the four analogs examined. The compounds were also active in the intraperitoneal leukemia L1210 and P388 systems as well as in B16 melanoma and Lewis lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159704     DOI: 10.1021/jm00242a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.

Authors:  E A Neuwelt; S A Dahlborg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

Review 2.  Spiromustine: a new agent entering clinical trials.

Authors:  D D Shoemaker; P J O'Dwyer; S Marsoni; J Plowman; J P Davignon; R D Davis
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 3.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.

Authors:  J S Driscoll; D G Johns; J Plowman
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.